{ "company_number": "08229389", "name": "Vaccine Formulation Institute Limited", "url": "/company/08229389", "status": "Active", "is_active": true, "company_type": "PRI/LTD BY GUAR/NSC (Private, limited by guarantee, no share capital)", "incorporated_on": "2012-09-26", "dissolved_on": null, "sic_codes": [ { "code": "86220", "description": "Specialists medical practice activities", "section": "Q", "section_name": "Human health and social work activities", "url": "/sic/86220" } ], "registered_address": { "id": 1257473, "url": "/address/1257473", "line1": "5 GODALMING BUSINESS CENTRE", "line2": "WOOLSACK WAY", "post_town": "GODALMING", "county": "SURREY", "country": "UNITED KINGDOM", "postcode": "GU7 1XW" }, "companies_house_url": "https://find-and-update.company-information.service.gov.uk/company/08229389", "previous_names": [ { "name": "Vaccine Formulation Services Limited", "ceased_on": "2016-06-13" } ], "care_of": "", "po_box": "", "country_of_origin": "United Kingdom", "accounts": { "next_due": "2027-09-30", "last_made_up": "2025-12-31", "category": "TOTAL EXEMPTION FULL", "filings": [ { "url": "/company/08229389/accounts/2025-12-31", "made_up_date": "2025-12-31", "period_start": "2025-12-31", "period_end": "2025-12-31", "entity_name": "Vaccine Formulation Institute Limited", "dormant": false, "average_employees": "2.00", "tangible_fixed_assets": null, "debtors": null, "cash_bank_in_hand": null, "current_assets": null, "creditors_due_within_one_year": "14652.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "-14652.00", "total_assets_less_current_liabilities": "-14652.00", "net_assets_liabilities": "-14652.00", "called_up_share_capital": null, "profit_loss_account_reserve": "-14652.00", "shareholder_funds": "-14652.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-May2026.zip" }, { "url": "/company/08229389/accounts/2024-12-31", "made_up_date": "2024-12-31", "period_start": "2024-12-31", "period_end": "2024-12-31", "entity_name": "Vaccine Formulation Institute Limited", "dormant": false, "average_employees": "2.00", "tangible_fixed_assets": null, "debtors": "2450.00", "cash_bank_in_hand": "10132.00", "current_assets": "12582.00", "creditors_due_within_one_year": "20027.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "-7445.00", "total_assets_less_current_liabilities": "198555.00", "net_assets_liabilities": "198555.00", "called_up_share_capital": null, "profit_loss_account_reserve": "198555.00", "shareholder_funds": "198555.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-August2025.zip" }, { "url": "/company/08229389/accounts/2023-12-31", "made_up_date": "2023-12-31", "period_start": "2023-12-31", "period_end": "2023-12-31", "entity_name": "Vaccine Formulation Institute Limited", "dormant": false, "average_employees": "2.00", "tangible_fixed_assets": null, "debtors": "52208.00", "cash_bank_in_hand": "30768.00", "current_assets": "82976.00", "creditors_due_within_one_year": "138101.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "-55125.00", "total_assets_less_current_liabilities": "150875.00", "net_assets_liabilities": "150875.00", "called_up_share_capital": null, "profit_loss_account_reserve": "150875.00", "shareholder_funds": "150875.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-July2024.zip" }, { "url": "/company/08229389/accounts/2022-12-31", "made_up_date": "2022-12-31", "period_start": "2022-12-31", "period_end": "2022-12-31", "entity_name": "Vaccine Formulation Institute Limited", "dormant": false, "average_employees": "2.00", "tangible_fixed_assets": null, "debtors": "364.00", "cash_bank_in_hand": "82515.00", "current_assets": "82879.00", "creditors_due_within_one_year": "149799.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "-66920.00", "total_assets_less_current_liabilities": "139080.00", "net_assets_liabilities": "139080.00", "called_up_share_capital": null, "profit_loss_account_reserve": "139080.00", "shareholder_funds": "139080.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-November2023.zip" }, { "url": "/company/08229389/accounts/2021-12-31", "made_up_date": "2021-12-31", "period_start": "2021-12-31", "period_end": "2021-12-31", "entity_name": "Vaccine Formulation Institute Limited", "dormant": false, "average_employees": "2.00", "tangible_fixed_assets": null, "debtors": "31432.00", "cash_bank_in_hand": "55378.00", "current_assets": "86810.00", "creditors_due_within_one_year": "240783.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "-153973.00", "total_assets_less_current_liabilities": "52027.00", "net_assets_liabilities": "52027.00", "called_up_share_capital": null, "profit_loss_account_reserve": "52027.00", "shareholder_funds": "52027.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-May2022.zip" }, { "url": "/company/08229389/accounts/2020-12-31", "made_up_date": "2020-12-31", "period_start": "2020-12-31", "period_end": "2020-12-31", "entity_name": "Vaccine Formulation Institute Limited", "dormant": false, "average_employees": "2.00", "tangible_fixed_assets": "206000.00", "debtors": "70842.00", "cash_bank_in_hand": "146159.00", "current_assets": "217001.00", "creditors_due_within_one_year": "411119.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "-194118.00", "total_assets_less_current_liabilities": "11882.00", "net_assets_liabilities": "11882.00", "called_up_share_capital": null, "profit_loss_account_reserve": "11882.00", "shareholder_funds": "11882.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-September2021.zip" }, { "url": "/company/08229389/accounts/2019-12-31", "made_up_date": "2019-12-31", "period_start": "2019-12-31", "period_end": "2019-12-31", "entity_name": "Vaccine Formulation Institute Limited", "dormant": false, "average_employees": "0.00", "tangible_fixed_assets": "102805.00", "debtors": "31319.00", "cash_bank_in_hand": "1087910.00", "current_assets": "1119229.00", "creditors_due_within_one_year": "1158489.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "-39260.00", "total_assets_less_current_liabilities": "63545.00", "net_assets_liabilities": "58452.00", "called_up_share_capital": null, "profit_loss_account_reserve": "58452.00", "shareholder_funds": "58452.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-October2020.zip" }, { "url": "/company/08229389/accounts/2019-09-30", "made_up_date": "2019-09-30", "period_start": "2019-09-30", "period_end": "2019-09-30", "entity_name": "Vaccine Formulation Institute Limited", "dormant": false, "average_employees": null, "tangible_fixed_assets": "29956.00", "debtors": "10704.00", "cash_bank_in_hand": "593509.00", "current_assets": "604213.00", "creditors_due_within_one_year": "550636.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "53577.00", "total_assets_less_current_liabilities": "83533.00", "net_assets_liabilities": "78440.00", "called_up_share_capital": null, "profit_loss_account_reserve": "78440.00", "shareholder_funds": "78440.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-April2020.zip" }, { "url": "/company/08229389/accounts/2018-09-30", "made_up_date": "2018-09-30", "period_start": "2018-09-30", "period_end": "2018-09-30", "entity_name": "Vaccine Formulation Institute Limited", "dormant": false, "average_employees": null, "tangible_fixed_assets": "3447.00", "debtors": "20197.00", "cash_bank_in_hand": "324852.00", "current_assets": "345049.00", "creditors_due_within_one_year": "319657.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "25392.00", "total_assets_less_current_liabilities": "28839.00", "net_assets_liabilities": "28253.00", "called_up_share_capital": null, "profit_loss_account_reserve": "28253.00", "shareholder_funds": "28253.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-June2019.zip" }, { "url": "/company/08229389/accounts/2017-09-30", "made_up_date": "2017-09-30", "period_start": "2017-09-30", "period_end": "2017-09-30", "entity_name": "Vaccine Formulation Institute Limited", "dormant": false, "average_employees": null, "tangible_fixed_assets": "1521.00", "debtors": "49775.00", "cash_bank_in_hand": "64093.00", "current_assets": "113868.00", "creditors_due_within_one_year": "83060.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "30808.00", "total_assets_less_current_liabilities": "32329.00", "net_assets_liabilities": "32040.00", "called_up_share_capital": null, "profit_loss_account_reserve": "32040.00", "shareholder_funds": "32040.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-May2018.zip" }, { "url": "/company/08229389/accounts/2016-09-30", "made_up_date": "2016-09-30", "period_start": "2016-09-30", "period_end": "2016-09-30", "entity_name": "Vaccine Formulation Institute Limited", "dormant": false, "average_employees": null, "tangible_fixed_assets": null, "debtors": "13184.00", "cash_bank_in_hand": "21009.00", "current_assets": "34193.00", "creditors_due_within_one_year": "15758.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "18435.00", "total_assets_less_current_liabilities": "18435.00", "net_assets_liabilities": "18435.00", "called_up_share_capital": null, "profit_loss_account_reserve": "18435.00", "shareholder_funds": "18435.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-June2017.zip" }, { "url": "/company/08229389/accounts/2015-09-30", "made_up_date": "2015-09-30", "period_start": "2015-09-30", "period_end": "2015-09-30", "entity_name": "Vaccine Formulation Institute Limited", "dormant": false, "average_employees": null, "tangible_fixed_assets": null, "debtors": "28041.00", "cash_bank_in_hand": "197586.00", "current_assets": "225627.00", "creditors_due_within_one_year": "213053.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "12574.00", "total_assets_less_current_liabilities": "12574.00", "net_assets_liabilities": "12574.00", "called_up_share_capital": null, "profit_loss_account_reserve": "12574.00", "shareholder_funds": "12574.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-June2016.zip" } ], "pdf_only_filings": [ { "made_up_date": "2014-09-30", "filing_date": "2015-07-06", "form_type": "AA", "description": "accounts-with-accounts-type-total-exemption-small", "paper_filed": true, "pdf_url": "/company/08229389/accounts/2014-09-30.pdf", "companies_house_url": "https://find-and-update.company-information.service.gov.uk/company/08229389/filing-history/MzEyNjM0MjU1OGFkaXF6a2N4/document?format=pdf&download=0" }, { "made_up_date": "2013-09-30", "filing_date": "2014-06-26", "form_type": "AA", "description": "accounts-with-accounts-type-total-exemption-small", "paper_filed": true, "pdf_url": "/company/08229389/accounts/2013-09-30.pdf", "companies_house_url": "https://find-and-update.company-information.service.gov.uk/company/08229389/filing-history/MzEwMjU5MzU0NGFkaXF6a2N4/document?format=pdf&download=0" } ], "filing_history_url": "https://find-and-update.company-information.service.gov.uk/company/08229389/filing-history" }, "confirmation_statement": { "next_due": "2026-10-10", "last_made_up": "2025-09-26" }, "officers": [], "psc": [ { "name": "Nicolas Rene Collin", "kind": "individual-person-with-significant-control", "person_url": "/person/3689178", "controlling_company_url": null, "natures_of_control": [ "ownership-of-shares-25-to-50-percent", "voting-rights-25-to-50-percent" ], "notified_on": "2016-04-06", "ceased_on": null, "nationality": "French", "country_of_residence": "France", "source": "snapshot" }, { "name": "Patrice Martin Dubois", "kind": "individual-person-with-significant-control", "person_url": "/person/3827319", "controlling_company_url": null, "natures_of_control": [ "ownership-of-shares-25-to-50-percent", "voting-rights-25-to-50-percent" ], "notified_on": "2016-04-06", "ceased_on": null, "nationality": "Belgian", "country_of_residence": "Belgium", "source": "snapshot" } ], "external_links": [], "provenance": { "source": "snapshot", "first_seen_at": "2026-07-05T12:35:35.811816+00:00", "last_seen_snapshot": "2026-08-01", "retrieved_at": "2026-08-02T05:12:20.351914+00:00" }, "licence": "Open Government Licence v3.0", "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/", "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: Companies House." }